About Lyndra

The Team That Is Reinventing Medicine

It takes a visionary and determined team to create game-changing technology. Meet the team behind Lyndra’s LYNX^® drug delivery platform.

Learn more About Lyndra

Learn More about Lyndra

The Lyndra Story

Lyndra Therapeutics is pioneering long-acting oral therapies, a potential major advance in oral drug delivery. Lyndra’s proprietary LYNX^® drug delivery platform is designed to deliver medicine for a week or longer in an oral form.

It takes a visionary and determined team to create game-changing technology. Lyndra’s core purpose to reinvent medicine for a healthier world and its core values — value every voice; resilient to the core; I contribute, we deliver — make it a distinctive company with the dynamic, empowering and innovation-focused culture to succeed.

"When an unusual challenge is put in the hands of exceptional people, the work becomes energizing—and irresistible."

– Jessica Ballinger, President and CEO

$ 200 M

Lyndra has raised more than $380M to date through investors and partners, including $100M in non-dilutive grants.

Lyndra has achieved 25 active pharmaceutical ingredient (API) formulations.

Five therapeutic areas with clinical proof of concept, including psychiatry, Alzheimer's disease, opioid use disorder, cardiometabolic diseases and infectious diseases

Core Purpose

Reinvent medicine for a healthier world

A Team of Innovators

Lyndra’s visionary and determined team continues to break barriers in the quest to launch a major advance in oral drug delivery. Lyndra welcomes anyone who is excited by innovation and growth, demonstrates strong technical expertise, has sharp and collaborative problem-solving skills, and is energized by the opportunity and fast pace of an emerging biopharmaceutical company. The Lyndra team is working together to deliver multiple game-changing treatments through the LYNX^® drug delivery platform to meet the needs of patients and caregivers. Does Lyndra sound like a great fit for you?

"At Lyndra, everyone is necessary. Everyone is expected to work hard, to step outside their comfort zones and ultimately, to make a difference.”

Jessica Ballinger

President and CEO | Member of the Board

The Lyndra Culture

Working together to break barriers and reinvent medicine

The Lyndra team firmly believes that diversity of identity, experience and perspectives drives innovation. Lyndra’s visionary and determined team is why the company continues to break barriers, grow and thrive; a range of backgrounds and perspectives is critical to success. At Lyndra, equality and individuality are welcomed, valued, promoted and celebrated.

Lyndra's History

Lyndra’s story began in 2015 with revolutionary technology that emerged from the Langer Lab at MIT. Robert Langer, Sc.D., Giovanni Traverso, M.D., Ph.D., Andrew Bellinger, M.D., Ph.D. and Amy Schulman, J.D., founded the company to develop and expand the technology that would ultimately become the LYNX^® drug delivery platform. Since its founding, Lyndra has achieved rapid progress, formulating 25 therapies in the lab, with an additional 12 clinical trials completed and POC for oral weekly dosing in 5 therapeutic areas, validating the feasibility of its platform with multiple APIs.

2015

Founded on Innovation

Robert Langer, Sc.D., Giovanni Traverso, M.D., Ph.D., Andrew Bellinger, M.D., Ph.D. and Amy Schulman, J.D., founded Lyndra Therapeutics.

2016

Preclinical Proof of Concept; NIH Grant

Lyndra began preclinical trials of the LYNX^® drug delivery platform with the help of a $0.3M grant from the National Institutes of Health (NIH). The data proved that the platform worked.

2017

Human Proof of Concept; Series A; Additional Grants

The LYNX^® drug delivery platform demonstrated proof of concept in human subjects. Lyndra completed a $23M Series A funding round, established a $105M partnership with AbbVie and received $10M in grants (Bill & Melinda Gates Foundation and NIH).

2018

Phase 1 Studies; Additional Grants

The safety of the LYNX^® drug delivery platform and predictable pharmacokinetics was demonstrated in Phase 1 clinical trials. Lyndra’s grant funding continued to grow via additional grants from the NIH ($18M) and the Bill & Melinda Gates Foundation ($13M).

2019

First Pre-IND; Expanded Phase 1 Pipeline; Series B; Additional Grants; Partnership

A follow-on Phase 1 study with a combination product including two different APIs in a single LYNX^® capsule demonstrated consistent pharmacokinetics of the two actives at target levels, insensitivity to food effects and provided further evidence of the safety of the LYNX^® oral drug delivery platform. Lyndra completed a $60M Series B funding round, established a $122M partnership with Gilead and received additional grants from the NIH ($19M) and the US Department of Defense ($3M).

2020

Oral Weekly Risperidone (LYN-005) IND Submission and Phase 1 and 2 Clinical Trials; GMP Manufacturing Established

The pandemic did not keep Lyndra from forging ahead. Lyndra continued to grow, adding to its workforce, expanding its pipeline, and initiating its first Phase 2 study using the LYNX^® drug delivery platform. Lyndra opened a state-of-the-art GMP manufacturing facility in Lexington, MA. Lyndra also received additional grants from the Bill & Melinda Gates Foundation ($2M) and the NIH ($1M).

2021

Positive Phase 2 Data for Oral Weekly Risperidone (LYN-005) and End of Phase 2 FDA Meeting; IND Application and Fast Track Designation for Oral Weekly Levomethadone (LYN-014); Series C

Oral weekly risperidone (LYN-005) for the treatment of schizophrenia met its Phase 2 endpoints and a positive End of Phase 2 meeting with the FDA established a path to approval. An IND was filed for oral weekly levomethadone (LYN-014) for the maintenance treatment of opioid use disorder, and the program received Fast Track designation from the FDA. Lyndra completed a $60.5M Series C funding round and grew its workforce to over 100 employees.

2022

Innovation and trial initiation

Lyndra’s LYNX^® drug delivery platform won the Fierce Life Sciences Innovation Award for Drug Delivery Technology; the first patient was dosed in a Phase 1 trial of oral bi-weekly ivermectin.

2023

Pivotal Study and Leadership

Oral weekly risperidone (LYN-005) initiated pivotal clinical trials. President and Chief Operations Officer Jessica Ballinger appointed President and CEO. Lyndra completed a $20M Series D funding round and a $101M Series E funding round.

Investors

Thanks to more than $380M raised to date from investors and partners, Lyndra has advanced the LYNX^® drug delivery platform, prepared oral weekly risperidone (LYN-005) for pivotal trials and opened a custom-built GMP manufacturing facility in Lexington, MA. There are broad opportunities for the LYNX^® drug delivery platform still waiting to be unlocked.

Partners

Lyndra has rapidly advanced and de-risked its LYNX^® drug delivery platform with support from partners who also see the platform’s potential across an array of oral compounds. Lyndra’s global and public health programs are supported by the Bill & Melinda Gates Foundation and the National Institutes of Health’s National Institute on Drug Abuse (NIDA). There are opportunities for partnership on these and other programs, including programs for which Phase 1 clinical data is available (i.e., Alzheimer’s disease, type 2 diabetes, dyslipidemia). Lyndra welcomes inbound requests from pharmaceutical partners and others interested in discussing how the LYNX^® drug delivery platform could optimize their therapies for long-acting oral drug delivery.

About Lyndra

Continue learning more